Vascular adhesion protein-1 as in vivo target for imaging of leukocyte transendothelial migration in inflammation
Pysyvä osoite
Verkkojulkaisu
DOI
Tiivistelmä
Inflammation is related to many diseases, such as atherosclerosis, rheumatoid arthritis and metabolic diseases. Vascular adhesion protein-1 (VAP-1) is an endothelial adhesion molecule involved in leukocyte trafficking cascades from blood circulation to the sites of inflammation. In normal condition, VAP-1 is stored in intracellular granules. During inflammation it is rapidly translocated from the intracellular storage granules to the endothelial cell surface. Siglec-9 is a leukocyte ligand of VAP-1 and Siglec-9 motif containing peptide can be used as a positron emission tomography (PET) tracer for in vivo imaging of inflammation-related diseases.
For this study, radiolabeled Siglec-9 was evaluated for feasibility as a tracer in imaging orthopaedic implant infection in rats, synovitis in rabbits, turpentine oil-induced inflammation in rats and atherosclerosis in mice. Dynamic PET imaging was performed using [68Ga]DOTA-Siglec-9 or [18F]FDR-Siglec-9. After PET imaging various tissues were collected for ex vivo measurements with a gamma counter. Inflamed tissues were further studied with the digital autoradiography and histological staining. The expression of luminal VAP-1 in inflamed tissues was also studied by means of immunohistochemical stainings.
Inflammation in different experimental settings were clearly visualized with [68Ga]DOTA-Siglec-9 PET. The [18F]FDR-Siglec-9 uptake in atherosclerotic mouse model and an acute sterile inflammation in a turpentine oil-induced rat model were comparable with [68Ga]DOTA-Siglec-9. Anti-inflammatory therapy with VAP-1 inhibitor (LJP1586) reduced macrophages in atherosclerotic plaques in mice. The expression of luminal VAP-1 in inflamed tissue was verified with fluorescence-based immunohistochemistry.
In conclusion, [68Ga]DOTA-Siglec-9 and [18F]FDR-Siglec-9 are promising imaging agents for in vivo imaging of inflammation. [68Ga]DOTA-Siglec-9 was able to detect inflammation already in its early stage. VAP-1 is a promising target for both anti-inflammatory therapy and molecular imaging of inflammation.
Kuvaus
Siirretty Doriasta
Sarja
Turun yliopiston julkaisuja. Sarja D, Medica – Odontologica|1295
Saavutettavuusominaisuudet
Ei tietoa saavutettavuudesta